Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
Maree McCabe, CEO of Dementia Australia, writes about the Australian government's recent $229 million funding allocation to dementia in the 2021-2022 budget.
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
Third year university students in Bandar Seri Begawan, Brunei Drussalam reflect on their community experience with ADI member demensia Brunei (dB).
Davos Alzheimer's Collaborative (DAC) Co-chairs, Arnaud Bernaert and George Vradenburg, write about how DAC is building a coalition in order to accelerate Alzheimer's and dementia innovation.
Cohort Studies of Memory in an International Consortium